All In MedTech

Device Trial Radar · NCT06374225

Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration Intervention

Strategy to Avoid Excessive Oxygen Using an Autonomous Oxygen Titration Intervention (SAVE-O2 AI)

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 300 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

300

Actual

Start

Apr 29, 2024

Primary completion

Dec 7, 2025

Study completion Jan 9, 2026

Sponsor

Lead sponsor
University of Colorado, DenverAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
United States Department of Defense; O2matic ApS; IDTS Medical, Inc.
First posted
Apr 18, 2024

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a multicenter randomized controlled trial to determine the effectiveness of a closed loop/autonomous oxygen titration system (O2matic PRO100) to maintain normoxemia (goal range SpO2 90-96%, target 93%) during the first 72 hours of acute injury or illness, compared to standard provider-driven methods (manual titration with SpO2 target of 90-96%).

Conditions

  • Critical Illness
  • Wounds and Injury
  • Disease Attributes
  • Pathologic Processes

Interventions

  • Automated Titration (O2matic)Device

    The patient will receive supplemental oxygen titrated using an autonomous oxygen titration device. The patient will be monitored and vital signs documented by the site's usual SpO2 assessments, but oxygen titration will occur automatically through the O2matic PRO100 device during the intervention period, unless there is a safety concern. The SpO2 range programmed into the PRO100 is 92-94%. The acceptable SpO2 range for the protocol is 90-96%. If a patient requires \>15lpm or other signs of advancing respiratory failure, they will be taken off the autonomous oxygen and transitioned to higher flow oxygen devices or mechanical ventilation per usual clinical care. If the patient is not receiving any supplemental oxygen per the autonomous titration, the clinical team may remove the oxygen delivery device from the patient, but the patient should remain connected to the PRO100 for the duration of the intervention period for data collection and to monitor for new supplemental oxygen needs.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Time Spent Within the Targeted Normoxemia RangeTime frame: during first 72 hours after randomization, censored at hospital discharge, escalation to high flow nasal oxygen/mechanical ventilation, or death if prior to 72 hours.

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • University of Colorado

    Aurora, Colorado

  • Atrium Health Wake Forest Baptist Medical Center

    Winston-Salem, North Carolina

  • Oregon Health and Sciences University

    Portland, Oregon

1 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.